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Cancer gets the red 
light 
Pharmacyclics, Inc. 
The triumvirate of cancer therapy - 
chemotherapy. radiotherapy and 
surgcr) - is being challenged by 3 
new method of trcatmcnt. 
Photodyn;mlic therap): (PLYT) uses 
red light to activate other\visc 
benign drugs, and its specificity is 
u inning over clinicians. 
“Photodynamic therapy is going to 
be well accepted because of the, 
minimal side effects and 10~ cost,” 
says David L1olphin of QL’I’ 
I’hoto’rherapeutics. Inc. (Yancouver, 
Ginada). 
QL:r is marketing PhotofrinB, 
the only PDT drug to be approved in 
the IISX. But sueral other 
companies arc racing to get the next 
generation of drugs onto the market. 
As Gth PhotofrinO, these drugs are 
hascd on porphyrins, the four-p):rrole 
rings seen in hemc and chloroph>~ll 
(Figure 1). 
One of QL’l”s future competitors 
is Pharmac~clics. Inc. of Sunn);vale, 
California. The Pharmaqclics drugs 
arc based on the expanded porphyrin 
ring of texaphg;rin, synthesized by 
Jonathan Sesslcr (I.ni\ersity of 
‘Ii-xus, Austin). The larger ring of 
conjugated bonds increases the 
~1 ayelength of absorption, and so 
clinicians can USC light that 
penetrates deeper into tissues. The 
improved localization of texaphyrin 
to tumors ~3s an unexpected bonus. 
From clinic to chemist and back again 
Sessler has more reason than most to 
bc moti\Tated in his work. 1Vhilc ;I 
graduate student in chemistry, he got 
first hand experience of the 
imperfect and imprecise nature of 
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cancer treatments as he Figure 1 ________ 
fought off Hodgkin’s 
disuse. The physician who 7 
pulled him through was 
Richard hliller, now the 
President and CEO of I 
Pharmacyclics. “Someda).” 
says Sessler, “\VC \z ill write 
the hook and make a 
fortune.” 
Scssler originally 
planned to fill the larger 
hole in tcxaph\-rin \rith 
radioisotopes. The 
comhin~tion could then be 
linked to an antihod\ 
targeted to ;I cancer cell. In 
the end the texaphyrin 
localized to cancer cells 
hettcr if there \~tls no 
antibod?, probahl? bccausc 
the porph) rin has ;1 high 
affinity for lipoprotein 
particles in the 
bloodstream. Rapidly 
di\,iding cancer cells make 
large amounts of 
membrane, so the\- ha\,e 
hefty appetites fo; the Chemistry & Btology 
cholesterol in lipoprotein 
I _____, J 
particles. ‘I’he tcxaphyrin Some of the porphyrin-based drugs used for photodynamlc 
gets pulled in 3s a therapy. Shown are Scotia’s m-THPC, Miravant’s SnEtP, and Pharmacyclics’ lutetium texaphyrin. 
passenger. 
Sessler says that local 
attitudes colored his decision to 
make tcxaphyrin. “In ‘Texas. 
cver);thing is bigger,” he says. 
“\Vhen I srrivcd here I quickly; 
realized that making something 
bigger would bc the UX~ to go. 
Besides, if _vou name a molecule 
after your state you get early 
tenure.” 
The upshot for I’D7 is that 3 
larger metal, in this cxx lutetium. 
can fit into the texaphyrin to yield 
the final drug Lrl-‘lkx. ‘I’he lutetium 
improves the cfficienc)- with \z;hich 
the I,Ll-Tex, excited by light, 
undergoes a process called intcr- 
system crossing. Instcad of re- 
emitting the energy as fluorescence, 
the 1,~‘l’cx is converted to an 
excited triplet spin state. It can then 
undergo spin exchange \r-ith 
unreactive triplet oxygen. converting 
it to highly- reactive singlet ox)gcn 
c\‘en Lvhilc the 1,~‘I’cx rckertr to its 
original singlet state. 
Singlet oxygen “oxidizes 
whatever it hits,” sa)-s Sessler. \vith 
membrane lipids perhaps its most 
important target. A proportion of the 
target cells die soon after, often from 
ion leakage. but man) more die from 
necrosis after \.arious signaling 
molecules C;ILISC the destruction of 
the surrounding blood \.esscls. 
Texaphyrin as an electron sink 
Gadolinium is another lanthanide 
ion that can fit into the tcxaphyrin 
hole. ‘I’he resulting (Gd-Tcx is being 
used to increase the po\~er of 
treatments N ith radiation or 
chemicals such as adriamvcin or 
bleom~cin. \\‘hen these agents 
encounter \vucr they product 
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hydroxyl radicals and solvated 
electrons. With Gd-Tex around, the 
radicals have a longer life and so can 
do more damage. The imines of the 
texaphyrin probably act as an 
electron sink, preventing the radicals 
from recombining with the electrons 
to form inactive hydroxide ions. 
Unlike lutetium, gadolinium is 
paramagnetic, meaning that the 
oscillations of its unpaired electron 
can be detected by magnetic 
resonance imaging. An imaging agent 
made of gadolinium and zeolite is 
providing Pharmacyclics with some 
cash while Lu-Tex winds its way 
through cancer trials. 
Texaphyrin on trial 
A Phase II trial is underway using 
Lu-Tex for recurrent breast cancer, 
and Gd-Tex is in a Phase II trial for 
the treatment (with radiation) of 
cancers that have metastasized to 
the brain. The National Cancer 
Institute (NCI) has also recognized 
the potential of Lu-Tex and Gd-Tex, 
and is funding grants for 
investigators wanting to run trials 
with these drugs for bladder, ovarian, 
pancreatic and primary brain cancers 
(Lu-Tex) and head and neck, 
pancreatic, lung and primary brain 
cancers (Gd-Tex). “It is wonderful 
for us,” says Markus Renschler, the 
Director of Clinical Research, 
“because we are tapping into the 
brain trust of the country through 
the NCI.” 
Pharmacyclics also has promising 
preclinical data on the use of Lu-Tex 
for atherosclerosis. The foamy 
macrophages that are part of 
atherosclerotic plaques ingest large 
amounts of cholesterol, and once 
again the Lu-Tex comes along for 
the ride. 
After local delivery, the drug is 
concentrated -35fold in the plaques 
as compared to neighboring tissue 
(the concentration in tumors is 
lo-15fold over background). The 
light is delivered using lasers and 
fiber optics, and because of its high 
wavelength it is not absorbed by 
passing red blood cells. 
Competitors 
While trials are ongoing, QLT has 
the market to itself. “Photofrin 
probably has at least three to four 
years, probably more than that, 
before any competing drugs can be 
approved,” says Dolphin. It is 
currently approved for esophageal 
cancer, and approval for small cell 
lung cancer is pending. PhotofrinB, 
a mixture of porphyrin oligomers, 
was developed after early 
experiments with natural product 
isolates. It is excited by lower 
wavelengths of light than the new 
drugs, and patients who use 
PhotofrinB are photosensitive, and 
so have to avoid the sun for up to a 
month after treatment. The 
photosensitivity may not be 
acceptable for non-life-threatening 
diseases, says Dolphin, but for 
chemotherapy patients it is small fry. 
And the lower wavelengths are good 
enough for the many applications 
that do not require deep penetration. 
“It works on most solid tumors,” 
says Thomas Dougherty, a PDT 
pioneer at Roswell Park Cancer 
Institute in Buffalo, New York. 
“That’s the bottom line.” 
That doesn’t stop companies like 
Pharmacyclics from claiming many 
advantages for their drugs. According 
to Pharmacyclics, Lu-Tex shows 
almost no photosensitivity, but has 
higher selectivity, allowing the 
treatment of tumors that are spread 
over wide areas. Lu-Tex is water 
soluble and easily clears the body, 
and it homes to tumors rapidly, so 
that light treatment can be on the 
same day as the drug injection (this 
is not the case for PhotofrinB). 
Other companies claim similar 
advantages for their drugs. Scotia 
Quanta Nova of Guildford, UK, has a 
drug called m-THPC that has very 
high activity, and so light treatments 
can be very brief. Ilnfortunately 
severe photosensitivity accompanies 
this increased activity. QLT’s second 
drug, BPDMA, causes very little 
photosensitivity and is being used in 
trials for age-related macular 
degeneration (AMD), the most 
common cause of blindness in the 
elderly. QLT hopes that the drug 
treatment will seal the leaky blood 
vessels that cause AMD. A drug 
promoted by Miravant Technologies 
(Santa Barbara, California) is also 
being used for AMD. The drug, 
called tin ethyl etiopurpurin (SnEt2) 
or PurlytinB, is also in Phase II/III 
studies for the treatment of 
metastatic breast cancer, basal cell 
carcinoma, and Kaposi’s sarcoma. 
The perfect drug 
Saturation of one of the four pyrrole 
units of porphyins (to form a chlorin) 
has boosted the absorbance maximum 
for the PDT drugs from the low to 
the high 600 nm range. The next step 
in raising the absorption maximum is 
to saturate a second pyrrole unit, as in 
bacteriochlorophyll. Pharmacyclics 
has bypassed this mechanism with the 
novel texaphyrin, which absorbs at 
732 nm. (Another advantage of the 
higher wavelength is that the light 
used for treatment is not absorbed by 
melanin, so pigmented melanomas 
can be targeted.) 
But the longer wavelengths are 
not desirable for all disease 
applications. “While there is this 
perception out there that long 
wavelengths are better, it’s not 
necessarily true,” says Byron 
Robinson of Miravant. “The shorter 
wavelengths of light can help you 
better limit the depth of light 
penetration at the target area.” 
Eventually, he says, the different 
drugs may complement each other, 
with the shorter wavelength drugs 
used for the more accessible 
conditions. 
The next step in PDT drug 
development will be to bring more 
logic to drug design. “For the therapy 
to evolve,” says Robinson, “we need 
to understand structure-activity 
relationships and what controls 
localization. The company that gets a 
grasp on that will be successful.” 
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